Resources
-
Navigating Complexity: A Strategic Framework
for Streamlining and Simplifying Antibody Drug
Conjugates Development and Potency Assay
Lifecycle Management
Speaker Presentation: Bioassays 2025
Toulokhonova Larisa, Merck & Co., Inc., 2025 -
Of Mice and (Wo)Men
Speaker Presentation: Bioassays 2025
Tomaschek Simone, Roche Diagnostics GmbH, 2025 -
Potency Revolution: MoA-Reflective Bioassays for
Next-Gen QC Testing
Speaker Presentation: Bioassays 2025
Takayanagi Ayumi, Chugai Pharmaceutical Co., Ltd., 2025 -
Elranatamab: Bispecific
mAb Bioassay Strategy
from R&D to
Commercialization
Speaker Presentation: Bioassays 2025
Richard Peter, Pfizer, Inc., 2025 -
Use of High Content Imaging to Enable Cell-based Potency Assay Development for ADCs
Speaker Presentation: Bioassays 2025
Mukherjee Madhumati, AstraZeneca, 2025 -
The Special World of Bioassay - Approach/Setup, Special Situations and Keys to Success
Speaker Presentation: Bioassays 2025
Mozier Ned, Pfizer, Inc. (Retired), 2025 -
Method Comparability and Method Bridging: Are They the Same Thing?
Roundtable Notes: Session 1 Table 2 Bioassays 2025
Method Comparability and Method Bridging: Are They the Same Thing? -
Lifecycle Management of Reagents and Equipment [Session 2]
Roundtable Notes: Session 2 Table 3 Bioassays 2025
Lifecycle Management of Reagents and Equipment -
Applications of AI for Bioassays [Session 2]
Roundtable Notes: Session 2 Table 1 Bioassays 2025
Applications of AI for Bioassays -
Applications of AI for Bioassays
Roundtable Notes: Session 1 Table 1 Bioassays 2025
Applications of AI for Bioassays -
Bioassays 2025 Summary Infographic
Summary Infographic: Bioassays 2025
-
Bioassays 2025 Scientific Program
Scientific Program: Bioassays 2025
-
Black Box, Fantasy, or Gödel’s Knot? Why Mass Spectrometry in Biopharma is None of These
Speaker Presentation: Consultants' Network March 2025
Skilton St John, Protein Metrics, LLC, 2025 -
Case Study:
Investigating
Monoclonal Antibody
Fragmentation Issues
Speaker Presentation: Consultants' Network March 2025
Schenerman Mark, CMC-MAS Biotech, 2025 -
Managing/Leveraging CMOs and CTOs for Lifecycle Success [Session 1]
Roundtable Notes: Session 1 Table 7 WCBP 2025
Managing/Leveraging CMOs and CTOs for Lifecycle Success [Session 1] -
Wide-Spread Adoption of High-Volume Delivery Subcutaneously - What’s the Hold-Up
Roundtable Notes: Session 1 Table 15 WCBP 2025
Wide-Spread Adoption of High-Volume Delivery Subcutaneously - What’s the Hold-Up -
What Are the New Alternate Lipids for Lipid Nanoparticles
Roundtable Notes: Session 1 Table 17 WCBP 2025
What Are the New Alternate Lipids for Lipid Nanoparticles -
Vaccine Manufacturing New Technologies for mRNA Production
Roundtable Notes: Session 2 Table 15 WCBP 2025
Vaccine Manufacturing New Technologies for mRNA Production -
The Road to One Global CMC Dossier [Session 1]
Roundtable Notes: Session 1 Table 5 WCBP 2025
The Road to One Global CMC Dossier [Session 1] -
The Road to One Global CMC Dossier [Session 2]
Roundtable Notes: Session 2 Table 5 WCBP 2025
The Road to One Global CMC Dossier [Session 2]